2022
Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials
Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. Kidney International Reports 2022, 7: 1939-1950. PMID: 36090489, PMCID: PMC9458993, DOI: 10.1016/j.ekir.2022.06.005.Peer-Reviewed Original ResearchChronic kidney diseaseEnd-stage kidney diseaseSevere kidney dysfunctionKidney diseaseKidney dysfunctionAdvanced kidney diseaseOptimal clinical careCancer drug trialsNumber of patientsNarrow therapeutic indexInitial clinical studiesKidney replacement treatmentPreregistration studiesKidney functionCancer careReplacement treatmentCancer trialsClinical trialsEffective dosingClinical studiesTreatment decisionsDrug trialsBeneficial drugsClinical carePatientsImaging Modalities for Acute Tubulointerstitial Nephritis
Baker M, Perazella M. Imaging Modalities for Acute Tubulointerstitial Nephritis. 2022, 257-266. DOI: 10.1007/978-3-030-93438-5_20.ChaptersAcute tubulointerstitial nephritisTubulointerstitial nephritisAcute kidney injury diagnosisNonspecific constitutional symptomsChronic kidney diseaseImaging modalitiesCurrent imaging modalitiesEmission Tomography ImagingPositron emission tomography (PET) imagingNon-invasive diagnosisConstitutional symptomsFlank painMost patientsKidney diseaseKidney failureCase reportInjury diagnosisRadiographic cluesClinical dataCommon causeGallium uptakeCharacteristic signsSymptomsDiagnosisTomography imaging
2021
The Crystalline Nephropathies
Perazella MA, Herlitz LC. The Crystalline Nephropathies. Kidney International Reports 2021, 6: 2942-2957. PMID: 34901567, PMCID: PMC8640557, DOI: 10.1016/j.ekir.2021.09.003.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseKidney injuryCrystalline nephropathyKidney diseaseCrystal depositionFurther kidney injuryIntrarenal crystal depositionUrinary sediment findingsUrine sediment examinationTubular obstructionHistologic findingsPathologic aspectsNephropathyClinical standpointInjuryTubular luminaSediment examinationFluid physiologyIdentification of crystalsCliniciansDiseaseIndirect cytotoxicityBiopsyInflammationPARP inhibitors and the Kidney
Deshpande P, Perazella M, Jhaveri K. PARP inhibitors and the Kidney. Journal Of Onco-Nephrology 2021, 5: 42-47. DOI: 10.1177/2399369320987090.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseIschemic acute kidney injuryEnd-stage kidney diseaseKidney diseaseSepsis-related acute kidney injuryAdvanced chronic kidney diseasePARP inhibitorsPoly (ADP-ribose) polymeraseIncrease serum creatinineUse of PARPisBreast cancer gene mutationsStage kidney diseaseAnti-cancer effectsCancer gene mutationsSafe dosingKidney injurySerum creatinineKidney functionKidney effectsClinical trialsLong-term effectsAnimal modelsCellular necrosisPARPis
2020
Onconephrology: The intersections between the kidney and cancer
Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA A Cancer Journal For Clinicians 2020, 71: 47-77. PMID: 32853404, DOI: 10.3322/caac.21636.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseDrug-induced nephrotoxicityKidney diseaseElectrolyte disordersAcute kidney injuryStem cell transplantationParaneoplastic glomerulonephritisKidney injuryCell transplantationTherapeutic regimensCollaborative careCancerDiseasePatientsOnconephrologyNew subspecialtySpecific training programsNephrotoxicityDisordersTraining programGlomerulonephritisRegimensNephrologistsTransplantationOncologistsNSAIDs in CKD: Are They Safe?
Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? American Journal Of Kidney Diseases 2020, 76: 546-557. PMID: 32479922, DOI: 10.1053/j.ajkd.2020.03.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsChronic kidney diseaseGlomerular filtration rateFiltration rateRisk factorsHigh pain burdenAcute kidney injuryManagement of painAnti-inflammatory drugsCKD populationNSAID useKidney injuryPain burdenPain controlHeart failureComorbid conditionsElectrolyte derangementsKidney diseaseSafety dataDrug effectsPatientsIndividualized basisDrug metabolismProgressive lossCautious useNomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International 2020, 97: 1117-1129. PMID: 32409237, DOI: 10.1016/j.kint.2020.02.010.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseGlomerular filtration rateKidney diseaseKidney functionKDIGO definitionConsensus conferenceSeverity of CKDEnd-stage kidney diseaseAcute kidney diseaseAbsence of symptomsGlobal Outcomes (KDIGO) Consensus ConferenceKDIGO guidelinesKidney injuryKidney failureKidney measuresFiltration rateWorldwide burdenGlobal outcomeKidney structureDiseaseHealth communitySeverityFollowing recommendationsMore effective communicationSGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressure18 Adverse kidney effects of immunotherapies
SALY D, PERAZELLA M. 18 Adverse kidney effects of immunotherapies. 2020, 166-182.e3. DOI: 10.1016/b978-0-323-54945-5.00027-8.Peer-Reviewed Original ResearchKidney diseaseDrug-induced kidney diseaseHigh-dose interleukin-2B-cell acute lymphoblastic leukemiaChimeric antigen receptor T cellsAntigen receptor T cellsAdverse kidney effectsImmune checkpoint inhibitorsChronic kidney diseaseChronic kidney injuryNumber of medicationsReceptor T cellsAcute lymphoblastic leukemiaConventional chemotherapeutic drugsAcid-base disturbancesOlder immunotherapiesCheckpoint inhibitorsKidney injuryNovel immunotherapiesNew immunotherapiesCancer patientsKidney effectsKidney lesionsLymphoblastic leukemiaImmune cells
2018
The adverse kidney effects of cancer immunotherapies
Saly D, Perazella M. The adverse kidney effects of cancer immunotherapies. Journal Of Onco-Nephrology 2018, 2: 56-68. DOI: 10.1177/2399369318808806.Peer-Reviewed Original ResearchChronic kidney diseaseKidney diseaseCancer immunotherapyInterleukin-2High-dose interleukin-2Chimeric antigen receptor T cellsAntigen receptor T cellsMore effective treatment optionsAdverse kidney effectsImmune checkpoint inhibitorsAcute kidney diseaseEffective treatment optionReceptor T cellsCase-based reviewCancer therapyGroup of drugsNew cancer immunotherapiesCancer treatment armamentariumConventional chemotherapeutic drugsList of cancersOlder immunotherapiesCheckpoint inhibitorsTreatment armamentariumNew immunotherapiesTreatment options35 Kidney Disease Caused by Therapeutic Agents
Perazella M, Shirali A. 35 Kidney Disease Caused by Therapeutic Agents. 2018, 334-344. DOI: 10.1016/b978-0-323-47794-9.00035-4.BooksKidney diseaseTherapeutic agentsDrug-induced renal toxicityProteinuria/nephrotic syndromeFrequent adverse consequencesChronic kidney diseaseChronic kidney injuryDrugs of abuseSubgroup of individualsDrug nephrotoxicityKidney injuryMost medicationsNephrotoxic drugsTubular dysfunctionNephrotic syndromeRenal toxicityDrug therapyRisk factorsTherapeutic medicationsRenal syndromeAppropriate careMedicationsNephrotoxicitySyndromeAdverse consequences
2016
Drug-Induced Hypertension in Chronic Kidney Disease
Vichot A, Perazella M. Drug-Induced Hypertension in Chronic Kidney Disease. 2016, 261-298. DOI: 10.1007/978-1-4939-6436-9_12.Peer-Reviewed Original ResearchChronic kidney diseaseCardiovascular complicationsKidney diseaseEnd-stage renal diseaseStrong risk factorHypertensive effectInflammatory syndromeBlood pressureRenal diseaseCounter medicationsMyocardial infarctionRisk factorsPhysiologic alterationsMood disordersHealthcare providersPatientsHypertensionDiseaseComplicationsMedicationsDrugsRiskPainInfarctionProviders
2015
New drug toxicities in the onco-nephrology world
Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney International 2015, 87: 909-917. PMID: 25671763, DOI: 10.1038/ki.2015.30.Peer-Reviewed Original ResearchConceptsKidney injuryAnticancer medicationsAdverse renal consequencesAcute kidney injuryChronic kidney diseaseLevel of proteinuriaMore effective therapiesRenal consequencesElectrolyte disturbancesKidney diseaseNephrotoxic effectsNephrotoxic potentialRisk factorsEffective therapyNephrotoxic manifestationsDrug toxicityNew agentsOld drugsNephrology communityResistant cancersClinical arenaAvailable evidenceMedicationsPatientsInjury
2009
Acute phosphate nephropathy
Markowitz GS, Perazella MA. Acute phosphate nephropathy. Kidney International 2009, 76: 1027-1034. PMID: 19675530, DOI: 10.1038/ki.2009.308.Peer-Reviewed Original ResearchConceptsAcute phosphate nephropathyAcute kidney injuryChronic kidney diseasePhosphate nephropathySubsequent chronic renal failureChronic tubular injuryAngiotensin receptor blockersChronic renal failureHigh-risk patientsRenal biopsy findingsClinical-pathological entityAggressive hydrationKidney injuryReceptor blockersBiopsy findingsRenal failureTubular injuryKidney diseasePathological entityRisk factorsFemale genderDistal tubulesEpidemiologic studiesDistal nephronEnzyme inhibitorsRenal Vulnerability to Drug Toxicity
Perazella MA. Renal Vulnerability to Drug Toxicity. Clinical Journal Of The American Society Of Nephrology 2009, 4: 1275-1283. PMID: 19520747, DOI: 10.2215/cjn.02050309.Peer-Reviewed Original ResearchConceptsDrug-induced kidney diseaseKidney diseaseRenal vulnerabilityRisk factorsAcute kidney injuryChronic kidney diseaseDrug-related factorsProteinuric renal diseaseKidney injuryRenal complicationsRenal injuryRenal diseaseNephrotoxic effectsRenal syndromeDrug toxicityDiseaseInjuryKidneyDrugsFactor categoriesToxinComplicationsPatientsFactorsTubulopathy
2004
Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease
Perazella M, Mosenkis A, Berns J. Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars In Dialysis 2004, 17: 411-416. PMID: 15461751, DOI: 10.1111/j.0894-0959.2004.17351.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableDiabetes Mellitus, Type 2Diabetic NephropathiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHeparin, Low-Molecular-WeightHumansKidney Failure, ChronicMalePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRisk AssessmentTreatment OutcomeConceptsLow molecular weight heparinIIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeEnd-stage renal diseaseMolecular weight heparinWeight heparinKidney diseaseGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsSafety of LMWHLarge prospective trialsMajor clinical trialsCardiac causesCoronary syndromeAppropriate dosingProspective trialRenal diseaseKidney functionAggressive interventionClinical benefitClinical trialsPatientsSignificant impairmentDisease